Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions

Pharmacological Reports

Volumn 65, Issue 2, 2013, Pages 399-409

  Blaszczyk, Barbara ^a,b   Szpringer, Monika ^c   Czuczwar, Stanislaw J ^d,e   Lason, Wladyslaw ^f,g  

^a High School of Economics and Law   (Poland)

^b Private Neurological Practice   (Poland)

^c JAN KOCHANOWSKI UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^f POLISH ACADEMY OF SCIENCES   (Poland)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antiepileptic drugs; Epilepsy; Hypersensitivity syndrome; Skin lesions

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ALLERGIC REACTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRESS SYNDROME; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; ERYTHEMA; ERYTHEMA NODOSUM; FEMALE; GENETIC POLYMORPHISM; HUMAN; IMMUNOREACTIVITY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; PRURITUS; RETROSPECTIVE STUDY; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 84879377289     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)71015-6     Document Type: Article

References (129)

1. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al.: Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 2011, 89, 806-815.
2. Alldredge BK, Knutsen AP, Ferriero D: Antiepileptic drug hypersensitivity syndrome. Pediatr Neurol, 1994, 10, 169-171.
3. Alvestad S, Lydersen S, Brodtkorb E: Rash from antiepileptic drugs: Influence by gender, age, and learning disability. Epilepsia, 2007, 48, 1360-1365.
4. Anderson GD: Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia, 2002, 43, Suppl 3, 53-59.
5. Arellano F, Sacristan JA: Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother, 1993, 19, 337-343.
6. Backonja MM: Use of anticonvulsants for treatment of neuropathic pain. Neurology, 2002, 59, Suppl 2, S14-S17.
7. Barbosa L, Berk M, Vorster M: A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry, 2003, 64, 403-407.
8. Barone CM, Bianchi MA, Lee B, Mitra A: Treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome in children. J Oral Maxillofac Surg, 1993, 51, 264-268.
9. Basta-Kaim A, Budziszewska B, Leoekiewicz M, Kubera M, Jaga G, Nowak W, Czuczwar SJ, Lasoñ W: Effects of new antiepileptic drugs and progabide on the mitogen-induced proliferative activity of mouse splenocytes. Pharmacol Rep, 2008, 60, 925-932.
10. Basta-Kaim A, Budziszewska B, Lasoñ W: Effects of antiepileptic drugs on immune system (Polish). Przegl Lek, 2008, 65, 799-802.
11. Beghi E, Shorvon S: Antiepileptic drugs and the immune system. Epilepsia, 2011, 52, Suppl 3, 40-44.
12. Beran RG, Berkovic SF, Dunagan FM, Vajda FJ, Danta G, Black AB,Mackenzie R: Double-blind, placebo controlled, crossover study of lamotrigine in treatmentresistant generalised epilepsy. Epilepsia, 1998, 39, 1329-1333.
13. Bertz RJ, Howrie DL: Diazepam by continuous intravenous infusion for status epilepticus in anticonvulsant hypersensitivity syndrome. Ann Pharmacother, 1993, 27, 298-301.
14. Baszczyk B: Epilepsy and allergy. Pharmacol Rep, 2010, 62, 429-430.
15. Bocquet H, Bagot M, Roujeau JC: Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg, 1996, 15, 250-257.
16. Bohan KH, Mansuri TF, Wilson NM: Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy, 2007, 27, 1425-1439.
17. Brodie MJ, Overstall PW, Giorgi L: Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res, 1999, 37, 81-87.
18. Brodie MJ, Richens A, Yuen AWC: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy, UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet, 1995, 345, 476-479.
19. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD et al.: Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry, 2002, 63, 1012-1019.
20. Chadwick D: Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double blind study, Vigabatrin European Monotherapy Study Group. Lancet, 1999, 354,13-19.
21. Chadwick D, Shaw MD, Foy P, Rawlins MD, Turnbull DM: Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry, 1984, 47, 642-644.
22. Chaffin JJ, Davis SM: Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother, 1997, 31, 720-723.
23. Chaiken BH, Goldberg BI, Segal JP: Dilantin hypersensitivity: report of a case of hepatitis with jaundice, pyrexia, and exfoliative dermatitis. N Engl J Med, 1950, 242, 897-898.
24. Chang DKM, Shear NH: Cutaneous reactions to anticonvulsants. Semin Neurol, 1992, 12, 320-337.
25. Chattergoon DS, McGuigan MA, Koren G, Hwang P, Ito S: Multiorgan dysfunction and disseminated intravascular coagulopathy in children receiving lamotrigine and valproic acid. Neurology, 1997, 49, 1442-1444.
26. Cheriyan S, Patterson R, Greenberger PA, Grammer LC, Latall J: The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc, 1995, 4, 151-155.
27. Choi H, Morrell MJ: Review of lamotrigine and its clinical applications in epilepsy. Expert Opin Pharmacother, 2003, 4, 243-251.
28. Cloyd J: Pharmacokinetic pitfalls of present antiepileptic medications. Epilepsia, 1991, 32, Suppl 5, S53-S65.
29. Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A: Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia, 2004, 45, 1049-1053.
30. Da Silva JA: Sex hormones and glucocorticoids: interactions with the immune system. Ann NY Acad Sci, 1999, 876, 102-117.
31. Eastham JH, Segal JL, Gomex MF, Cole GW: Reversal of erythema multiforme major with cyclophosphamide and prednisone. Ann Pharmacother, 1996, 30, 606-607.
32. Faught E, Morris G, Jacobson M, French J, Harden C, Montouris G, Rosenfeld W: Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing antiepileptic drug survey (PADS) group. Epilepsia, 1999, 40, 1135-1140.
33. Flowers FP, Araujo OE, Hamm KA: Phenytoin hypersensitivity syndrome. J Emerg Med, 1987, 5, 103-108.
34. Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C, Womble G, Casale EJ: Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia, 1999, 40, 973-979.
35. Frenia ML, Schauben P: Use of silver sulfadiazine in Stevens-Johnson syndrome. Ann Pharmacother, 1994, 28, 736-737.
36. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, Mikkelsen M et al.: Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand, 1993, 87, 224-227.
37. Gaedigk A, Spielberg SP, Grant DM: Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reaction. Pharmacogenetics, 1994, 4, 142-153.
38. Galindo PA, Borja J, Gomez E, Mur P, Gudin M, Garcia R, Encinas E et al.: Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol, 2002, 12, 299-304.
39. Gilman JT, Duchowny M: Allergic hypersensitivity to antiepileptic drugs: Past, present, and future. Epilepsia, 1998, 39, Suppl 7, Sl-S2.
40. Gleichmann H: Studies on the mechanism of drug sensitization: T-cell dependent popliteal lymph node reaction to diphenylhydantoin. Clin Immunol Immunopathol, 1981, 18, 203-211.
41. Greenwood RS: Adverse effects of antiepileptic drugs. Epilepsia, 2000, 41, Suppl 2, S42-S52.
42. Griebel ML: Acute management of hypersensitivity reactions and seizures. Epilepsia, 1998, 39, Suppl 7, S17-S21.
43. Grossman CJ: Regulation of the immune system by sex steroids. Endocrine Rev, 1984, 5, 435-455.
44. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A et al.: Lamotrigine-Associated rash: risk/benefit considerations in adults and children. Epilepsia, 1999, 40, 985-991.
45. Guibal F, Bastuji-Garin S, Chosidow P, Saiag P, Revuz J, Roujeau J: Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol, 1995, 131, 669-672.
46. Guitart J: Immunopathology of Stevens-Johnson syndrome. Allergy Proc, 1995, 16, 163-164.
47. Gupta A, Eggo MC, Uetrecht JP, Cripp AE, Daneman D, Rieder MJ, Shear MH et al.: Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther, 1992, 51, 56-67.
48. Gupta AK, Kopstein JE, Shear NH: Hypersensitivity reaction to terbinafine. J Am Acad Dermatol, 1997, 36, 1018-1019.
49. Halebian PH, Shires GT: Bum unit treatment of acute, severe exfoliating disorders. Annu Rev Med, 1989, 40, 137-147.
50. Handfield-Jones SE, Jenkins RE, Whittaker SJ, Besse CP, McGibbon DH: The anticonvulsant hypersensitivity syndrome. Br J Dermatol, 1993, 129, 175-177.
51. Haruda R: Phenytoin hypersensitivity: 38 cases. Neurology, 1979, 29, 1480-1485.
52. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, Resor SR Jr.: Predictors of lamotrigine-Associated rash. Epilepsia, 2006, 47, 318-322.
53. Horneff G, Lenard HG, Wahn V: Severe adverse reactions to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics, 1991, 23, 272-275.
54. Hung SI, Chung WH, Jee S, Chen WC, Chang YT, Lee WR, Hu SL et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics, 2006, 16, 297-306.
55. Hyson C, Sadler M: Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci, 1997, 24, 245-249.
56. Jones D, Chhiap V, Resor S, Appel G, Grossman ME: Phenytoin like hypersensitivity associated with lamotrigine. J Am Acad Dermatol, 1997, 36, 1016-1018.
57. Kakourou T, Klontza D, Soteropoulou F, Katamis C: Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr, 1997, 156, 90-93.
58. Kalis MM, Huff NA: Oxcarbazepine, an antiepileptic agent. Clin Ther, 2001, 23, 680-700.
59. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM: Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol, 1985, 121, 1548-1549.
60. Kim MJ, Lee KY: Bronchiolitis obliterans in children with Stevens-Johnson syndrome: follow-up with high resolution CT. Pediatr Radio1, 1996, 26, 22-25.
61. Kim PS, Goldfarb JW, Gaisford JW, Slater H: Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathological review with recommendations for a treatment protocol. J Burn Care Rehab, 1983, 4, 91-100.
62. Kleier RS, Breneman DL, Boiko S: Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol, 1991, 127, 1361-1364.
63. Knowles SR, Shapiro LE, Shear NH: Serious adverse drug reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol, 1996, 132, 934-939.
64. Knowles SR, Shapiro LE, Shear NH: Anticonvulsant hypersensitive syndrome. Incidence, prevention and management. Drug Saf, 1999, 6, 489-501.
65. Knutsen AP, Anderson J, Satayaviboon S, Slavin RG.: Immunologic aspects of phenobarbital hypersensitivity. J Pediatr, 1984, 105, 558-563.
66. Kramlinger KG, Phillips KA, Post RM: Rash complicating carbamazepine treatment. J Clin Psychopharmacol, 1994, 14, 408-413.
67. Lasoñ W, Dudra-Jastrzêbska M, Rejdak K, Czuczwar SJ: Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep, 2011, 63, 271-292.
68. Leeder JS, Riley RJ, Cook VA, Spielberg SP: Human anticytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther, 1992, 263,360-367.
69. Leeder JS: Mechanisms of idiosyncratic hypersensitivity to antiepileptic drugs. Epilepsia, 1998, 38, Suppl 7, S8-S16.
70. Licata AL, Louis ED: Anticonvulsant hypersensitivity reactions syndrome. Compr Ther, 1996, 22, 152-155.
71. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD: Safety of long-term lamotrigine in epilepsy. Epilepsia, 1997, 38, 881-886.
72. Maggs JL, Naisbitt DJ, Tettey JN, Pirmohamed M, Park BK: Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol, 2000, 13, 1075-1081.
73. Makin AJ, Fitt S, Williams R: Fulminant hepatic failure induced by lamotrigine. Br Med J, 1995, 311, 292.
74. Matsuo F: Lamotrigine. Epilepsia, 1999, 40, Suppl 5, S30-S36.
75. Mattson RH, Cramer JA, Collins JF, Smith DB, Gado-Escueta AV, Browne TR, Williamson PD et al.: Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonicclonic seizures. New Engl J Med, 1985, 313, 145-151.
76. Mattson RH, Cramer JA, Collins JF: A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonicclonic seizures in adults: The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med, 1992, 327, 765-771.
77. Messenheimer J, Mullens EL, Giorgi L, Young F: Safety review of adult clinical trial experience with lamotrigine. Drug Saf, 1998, 18, 281-296.
78. Messenheimer JA: Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci, 1998, 25, S14-S18.
79. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology, 2005, 64, 1134-1138.
80. Moudgil A, Porat S, Brunnel P, Jordan SC: Treatment of Stevens-Johnson syndrome with pooled human intravenous immune globulin. Clin Pediatr, 1995, 34, 48-51.
81. Nicholson RJ, Kelly KP, Grant IS: Leucopenia associated with lamotrigine. Br Med J, 1995, 310, 504.
82. Noskin GA, Patterson R: Outpatient management of Stevens-Johnson syndrome: a report of 4 cases and management strategy. Allergy Asthma Proc, 1997, 18, 29-32.
83. Osman M: Therapeutic implications of sex differences in asthma and atopy. Arch Dis Child, 2003, 88, 587-590.
84. Patterson R, Dykewicz MS, Gonzalzles A, Grammer LC, Green D, Greenberger PA, McGrath KG, Walker CL: Erythema multiforme and Stevens-Johnson syndrome: descriptive and therapeutic controversy. Chest, 1990, 98, 331-336.
85. Patterson R, Grammer LC, Greenberger PA, Lawrence ID, Zeiss CR, Detjen PF, Ganz MA et al:. Stevens-Johnson syndrome: effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc, 1992, 13, 289-295.
86. Patterson R, Miller M, Kaplan M, Doan T, Brown J, Detjen P, Grammer LC et al.: Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy, 1994, 73, 27-34.
87. Pelekanos J, Camfield P, Camfield C, Gordon K: Allergic rash due to antiepileptic drugs: clinical features and management. Epilepsia, 1991, 32, 554-559.
88. Pirmohamed M, Friedman PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L et al.: Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther, 2011, 89, 896-901.
89. Pirmohamed M, Kitteringham NR, Breckkenridge AM, Park BK: Detection of an auto-Antibody directed against human liver microsoma1 protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol, 1992, 33, 183-186.
90. Plantin P, Cartier H, Le Bihan G, Clouard P, Lellouche F, Leroy JP: Syndrome d'hypersensibilite medicamenteuse au cours d'un traitement par acide valproique. Presse Med, 1995, 24, 1624.
91. Powers NG, Carson NH: Idiosyncratic reactions to phenytoin. Clin Pediatr, 1987, 25, 120-124.
92. Prendiville JS, Hebert AA, Greenwald MJ, Esterly NB: Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr, 1989, 115, 881-887.
93. Prussick R, Shear NH: Dapsone hypersensitivity syndrome. J Am Acad Dermatol, 1996, 35, 346-349.
94. Rapp RP, Norton JA, Young B, Tibbs PA: Cutaneous reactions in head-injured patients receiving phenytoin for seizure prophylaxis. Neurosurgery, 1983, 13, 272-275.
95. Rasmussen JE: Erythema multiforme in children: response to treatment with systemic corticosteroids. Br J Dermatol, 1976, 95, 181-186.
96. Renfro L, Grant-Kelz JM, Daman LA: Drug-induced toxic epidermal necrolysis treated with cyclosporine. Int J Dermatol, 1989, 28, 441-444.
97. Reunanen M, Dam M, Yuen AW: A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res, 1996, 23, 149-155.
98. Richens A, Davidson DL, Cartlidge NE, Easter DJ: A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy: Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry, 1994, 57, 682-687.
99. Richens A: Safety of lamotrigine. Epilepsia, 1994, 35, Suppl 5, S37-S40.
100. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP: Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med, 1989, 110, 286-289.
101. Roujeau JC: Immune mechanisms in drug allergy. Allergol Int, 2006, 55, 27-33.
102. Roujeau JC: The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol, 1994, 102, 288-308.
103. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A et al.: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med, 1995, 333, 1600-1607.
104. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med, 1994, 331, 1272-1285.
105. Schaub JEM, Williamson PJ, Barnes EW, Trewby PN: Multisystem adverse reaction to lamotrigine. Lancet, 1994, 344, 481.
106. Schlienger RG, Shear NH: Antiepileptic drug hypersensitivity syndrome. Epilepsia, 1998, 39, Suppl 7, S3-S7.
107. Schlienger RG, Shapiro LE, Shear NH: Lamotrigineinduced severe cutaneous adverse reactions. Epilepsia, 1998, 39, Suppl 7, S22-S26.
108. Schmidt D, Sachdeo R: Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav, 2000, 1, 396-405.
109. Shamssain MH, Shamsian N: Prevalence and severity of asthma, rhinitis, and atopic eczema: the north east study. Arch Dis Child, 1999, 81, 313-317.
110. Shear NH, Spielberg SP: Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest, 1988, 82, 1826-1832.
111. Shiohara T, Kano Y, Takahashi R, Ishida T, Mizukawa Y: Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management. Chem Immunol Allergy, 2012, 97, 122-138.
112. Shorvon SD: The etiologic classification of epilepsy. Epilepsia, 2011, 52, 1052-1057.
113. Silber IB, Epstein JW: The treatment of chorea with phenyl-ethyl- hydantoin: a study of 28 cases. Arch Pediatr, 1934, 51, 373-382.
114. Singer L, Brook U, Romem M, Fried D: Vitamin A in Stevens-Johnson syndrome. Ann Ophthalmol, 1989, 21, 209-210.
115. Spielberg SP, Gordon GB, Blake DA, Mellits ED, Bross DS: Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther, 1981, 217, 386-389.
116. Spielberg SP, Shear NH, Cannon M, Hutson NJ, GundersonK: In-vitro assessment of a hypersensitivity syndrome associated with sorbinil. Ann Intern Med, 1991, 114, 720-724.
117. Stein J, Petrides PE: Anticonvulsive hypersensitivity syndrome (German). Dtsch Med Wochenschr, 1997, 122, 314-315.
118. Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, Park DM, Abbott R: Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia, 1999, 40, 601-607.
119. Strachan DP: Hay fever, hygiene, and household size. Br Med J, 1989, 299, 1259-1260.
120. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, Bilker WB, Pettitt D: Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med, 2003, 349, 1628-1635.
121. Sullivan JR, Shear NH: Drug eruptions and other adverse drug effects in aged skin. Clin Geriatr Med, 2002, 18, 21-42.
122. Talal N: Autoimmune mechanisms in patients and animal models. Toxicol Pathol, 1987, 15, 272-275.
123. Tennis P, Stem RS: Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology, 1997, 49, 542-546.
124. Tran C, Knowles SR, Liu BA, Shear NH: Gender differences in adverse drug reactions. J Clin Pharmacol, 1998, 38, 1003-1009.
125. Vercelli D: Mechanisms of the hygiene hypothesis -molecular and otherwise. Curr Opin Immunol, 2006, 18, 733-737.
126. Vittorio CC, Muglia JJ: Anticonvulsant hypersensitivity syndrome. Arch Intern Med, 1995, 155, 2285-2290.
127. Weber WW: Pharmacogenetics. University Press, New York, Oxford, 1997.
128. Wong IC, Mawer GE, Sander JW: Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother, 1998, 33, 1037-1042.
129. Zaccara G, Franciotta D, Perucca E: Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia, 2007, 48, 1223-1244.